Skip to main content
HANALL BIOPHARMA CO.,LTD logo

HANALL BIOPHARMA CO.,LTD — Investor Relations & Filings

Ticker · 009420 ISIN · KR7009420001 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2023-03-21 Annual Report
Country KR South Korea
Listing KO 009420

About HANALL BIOPHARMA CO.,LTD

http://www.hanallbiopharma.com/

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.

Recent filings

Filing Released Lang Actions
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for HanAll Biopharma Co., Ltd. for the fiscal year 2022 (Jan 1, 2022 - Dec 31, 2022). It contains comprehensive financial statements, management discussion and analysis, governance details, and auditor information. In the context of Korean corporate filings, the '사업보고서' is the equivalent of the US 10-K annual report, providing a full yearly overview of company activity and financial performance. FY 2022
2023-03-21 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for HanAll Biopharma. It contains the meeting agenda, details on voting procedures (including electronic voting), and management reference materials (business overview, financial statements, and board activity reports) required by law to be provided to shareholders prior to the meeting. This document is a standard proxy statement/notice package for an AGM.
2023-03-14 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for HanAll Biopharma. It details the date, location, and agenda items (such as director appointments and financial statement reporting) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2023-03-10 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from HanAll Biopharma titled 'Submission of Audit Report' (감사보고서 제출). It provides the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, revenue, profit), and details regarding the auditor (Samjong KPMG). While it contains financial data, it is a formal regulatory announcement of the audit report's submission rather than the full annual report (10-K) or a standalone audit report document. Given the structure and the nature of the disclosure, it fits the 'Report Publication Announcement' (RPA) category as it announces the completion and submission of the audit report. FY 2022
2023-03-06 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from HanAll Biopharma regarding a significant change in financial structure (revenue/profit change of 30% or more). This is a standard disclosure requirement in the Korean market (DART system) for companies to report preliminary financial results when there is a material variance from the previous year. It provides key financial highlights and reasons for the change, fitting the definition of an Earnings Release (ER) as it is an initial announcement of periodical financial results. FY 2022
2023-01-19 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (영업(잠정)실적) for HanAll Biopharma, detailing quarterly financial highlights such as revenue, operating profit, and net income for Q4 2022. It provides key financial metrics in a summary table format, which is characteristic of an initial earnings announcement rather than a full annual or interim report. Therefore, it fits the 'Earnings Release' (ER) category. Q4 2022
2023-01-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.